DVLT $2B HELMEX Mystery: Is the Address Really the Red Flag?
A beginner-friendly, fact-based DVLT brief on HELMEX, the UK address controversy, the non-binding $2B term sheet, the $25M payment, dilution, and board rights.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
8Results8Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
AIHS: after two disposals, the stock is a financing test
Senmiao Technology is a very high risk China ride-hailing auto-services microcap. The filings show a small post-disposal operating base, continuing losses, material weaknesses, Nasdaq compliance pressure and potentially heavy dilution mechanics.
OpenAGRZ: a vertical-farm microcap with a receivables test
Agroz has a real Malaysian CEA business and fast disclosed H1 2025 revenue growth, but AGRZ is a limited-disclosure microcap until it files FY2025 annual results, collects receivables and proves cash conversion.
OpenAGAE: the esports arena is now a listing-compliance story
Allied still has HyperX Arena Las Vegas, Z-Tech mobile games, and a balance-sheet cushion, but the current thesis is about the late 10-K, Nasdaq delisting risk, reverse-split vote, Knighted settlement, and whether revenue can ever catch the cost base.
OpenAdvanced Biomed: The No-Revenue Biotech That Just Swerved Into AI
Advanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
OpenAclarion: the $19M cash pile chasing a tiny Nociscan revenue line
Aclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reim
OpenACCESS Newswire: the tiny PR platform betting its old compliance cash flow on subscriptions
ACCESS Newswire has refocused around press release distribution, media monitoring, IR websites, events, and subscriptions after selling its Compliance business. The hook is improving ARR and retention; the risk is that the remaining company is still tiny, comp
OpenAcco Group (ACCL): the tiny compliance-services IPO that handed insiders 50-vote shares
Acco Group is not ACCO Brands. It is a Hong Kong and Singapore corporate-services microcap with US$4.9 million of FY2025 revenue, positive net income, an October 2025 Nasdaq IPO, and a January 2026 vote that approved a dual-class structure. The business is rea
Open